Voyager Therapeutics (MEX:VYGR) Cyclically Adjusted Revenue per Share: MXN38.52 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VYGR Voyager Therapeutics Inc MEX:VYGR
61 GF Score
Price MXN63.00
GF Value MXN32.88
! 5 Warning Signs
View Full Analysis

What is Voyager Therapeutics Cyclically Adjusted Revenue per Share?

Voyager Therapeutics MEX:VYGR 61 Cyclically Adjusted Revenue per Share is MXN38.52 as of Jun. 2026. GuruFocus rates MEX:VYGR with a GF Score™ of 61/100 and a GF Value™ of MXN32.88. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Voyager Therapeutics's adjusted revenue per share for the three months ended in Jun. 2026 was MXN0.912. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN38.52 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Voyager Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-13), Voyager Therapeutics's current stock price is MXN63.00. Voyager Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN38.52. Voyager Therapeutics's Cyclically Adjusted PS Ratio of today is 1.64.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Voyager Therapeutics was 4.34. The lowest was 1.29. And the median was 1.96.


Voyager Therapeutics  (MEX:VYGR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Voyager Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=63.00/38.52
=1.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Voyager Therapeutics was 4.34. The lowest was 1.29. And the median was 1.96.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Voyager Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Voyager Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics Cyclically Adjusted Revenue per Share Chart

Voyager Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 61.40 38.30

Voyager Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.17 32.23 38.30 37.52 38.52

MEX:VYGR vs NERV, DTIL, GLSI: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Voyager Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Cyclically Adjusted PS Ratio falls into.


MEX:VYGR
61GF Score
Voyager Therapeutics Inc MEX:VYGR
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Voyager Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.912/333.9520*333.9520
=0.912

Current CPI (Jun. 2026) = 333.9520.

Voyager Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.521 241.428 3.487
201612 1.908 241.432 2.639
201703 1.069 243.801 1.464
201706 0.820 244.955 1.118
201709 0.796 246.819 1.077
201712 4.252 246.524 5.760
201803 0.539 249.554 0.721
201806 1.582 251.989 2.097
201809 1.217 252.439 1.610
201812 1.220 251.233 1.622
201903 3.023 254.202 3.971
201906 23.333 256.143 30.421
201909 10.979 256.759 14.280
201912 16.723 256.974 21.732
202003 11.461 258.115 14.828
202006 17.878 257.797 23.159
202009 69.104 260.280 88.664
202012 3.487 260.474 4.471
202103 3.544 264.877 4.468
202106 0.719 271.696 0.884
202109 0.807 274.310 0.982
202112 15.233 278.802 18.246
202203 0.344 287.504 0.400
202206 0.374 296.311 0.422
202209 20.886 296.808 23.500
202212 -0.784 296.797 -0.882
202303 64.334 301.836 71.179
202306 1.912 305.109 2.093
202309 1.832 307.789 1.988
202312 30.305 306.746 32.993
202403 5.671 312.332 6.064
202406 9.388 314.175 9.979
202409 8.383 315.301 8.879
202412 2.258 315.605 2.389
202503 2.270 319.799 2.370
202506 1.669 322.561 1.728
202509 4.169 324.800 4.286
202512 4.685 324.054 4.828
202603 0.786 330.213 0.795
202606 0.912 333.952 0.912

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN38.52 mean?
Voyager Therapeutics (MEX:VYGR) has a Cyclically Adjusted Revenue per Share of MXN38.52 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Voyager Therapeutics and its competitors.
Is Voyager Therapeutics' Cyclically Adjusted Revenue per Share too high?
Voyager Therapeutics' current Cyclically Adjusted Revenue per Share is MXN38.52. Overall, Voyager Therapeutics has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Cyclically Adjusted Revenue per Share compare to NERV and DTIL?
Voyager Therapeutics' Cyclically Adjusted Revenue per Share of MXN38.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current Cyclically Adjusted Revenue per Share is MXN38.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Voyager Therapeutics (MEX:VYGR) has a current Cyclically Adjusted Revenue per Share of MXN38.52. The stock's GF Value™ is MXN32.88, compared to a current price of MXN63.00 — trading 91.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN38.52. Voyager Therapeutics' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Voyager Therapeutics (MEX:VYGR), the current Cyclically Adjusted Revenue per Share is MXN38.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (MEX:VYGR) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of MXN63.00 is trading 91.6% above its estimated GF Value™ of MXN32.88.

Key valuation signals for MEX:VYGR:

  • Cyclically Adjusted Revenue per Share: MXN38.52
  • GF Value™: MXN32.88 vs. price of MXN63.00 (91.6% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the MEX:VYGR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVT6:Germany
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
61GF Score

Get the complete analysis for MEX:VYGR

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN63.00
Price
MXN32.88
GF Value